PMID- 15338099
OWN - NLM
STAT- MEDLINE
DCOM- 20050323
LR  - 20181113
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 177
IP  - 1-2
DP  - 2004 Dec
TI  - Studies on the role of dopamine D1 receptors in the development and expression of 
      MDMA-induced behavioral sensitization in rats.
PG  - 100-10
AB  - RATIONALE: There is a large body of evidence indicating that the mesoaccumbens 
      dopamine pathway is critically involved in the expression of behavioral 
      sensitization to amphetamine and cocaine, but its role in the development of 
      sensitization to psychostimulants is not that sound. Very few studies, however, 
      have examined the role of dopamine transmission in 
      3,4-methylenedioxymethamphetamine (MDMA)-induced sensitization. OBJECTIVES: The 
      effects of the D1 receptor antagonist SCH 23390 on the development and expression 
      of MDMA-induced behavioral sensitization were investigated in rats. METHODS: 
      During the development phase of sensitization, SCH 23390 was administered 15 min 
      before every administration of MDMA. After 12 days of withdrawal, a MDMA 
      challenge dose was given and locomotor activity was measured. In separate 
      experiments, 15 min before the challenge injection of MDMA, SCH 23390 was 
      administered either systemically or directly into the core of the nucleus 
      accumbens (NAc) of MDMA-pretreated rats. RESULTS: SCH 23390 did not prevent the 
      development of MDMA-induced behavioral sensitization but completely blocked the 
      expression when given before the challenge dose of MDMA. The same results were 
      obtained when SCH 23390 was locally applied into the core of the NAc. 
      CONCLUSIONS: The present data suggest that D1 receptor stimulation is not 
      critical for the development of long-term MDMA sensitization, in agreement with 
      what has been reported for cocaine. By contrast, expression of sensitization 
      depends on the activation of D1 receptors located in the NAc core.
FAU - Ramos, Maria
AU  - Ramos M
AD  - Department of Pharmacology, School of Medicine, University of Navarra, 
      C/Irunlarrea, 1, 31008 Pamplona, Spain.
FAU - Goni-Allo, Beatriz
AU  - Goni-Allo B
FAU - Aguirre, Norberto
AU  - Aguirre N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040827
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Dopamine Antagonists/pharmacology
MH  - Male
MH  - Motor Activity/*drug effects/physiology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nucleus Accumbens/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Dopamine D1/antagonists & inhibitors/*physiology
MH  - Time Factors
EDAT- 2004/09/01 05:00
MHDA- 2005/03/24 09:00
CRDT- 2004/09/01 05:00
PHST- 2003/09/30 00:00 [received]
PHST- 2004/05/14 00:00 [accepted]
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2005/03/24 09:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - 10.1007/s00213-004-1937-0 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2004 Dec;177(1-2):100-10. doi: 
      10.1007/s00213-004-1937-0. Epub 2004 Aug 27.